Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 16, 2004, Pages 4257-4261

  Ivanova, Diana ^a   Rossin, Aurélie ^a   Gronemeyer, Hinrich ^a   Valla, Alain ^b   Cartier, Dominique ^b   Le Guillou, Régis ^b   Labia, Roger ^b  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b Lab Chim Biol Substances N   (France)

Author keywords

Apoptosis; Differentiation; Leukemia; RAR selectivity; Retinoids; Rexinoids

Indexed keywords

RETINOID DERIVATIVE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROMYELOCYTIC LEUKEMIA; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

CELL DEATH; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; HYDROCARBONS; LEUKEMIA, PROMYELOCYTIC, ACUTE; METHANE; RETINOIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3142661061     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.06.002     Document Type: Article

References (27)

1. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer. 1:2001;181-193
2. Zusi F.C., Lorenzi M.V., Vivat-Hannah V. Drug Discov. Today. 7:2002;1165-1174
3. Sporn M., Roberts A., Goodman D. The Retinoids, Biology, Chemistry and Medicine. 1994;Raven, New York
4. Altucci L., Gronemeyer H. Retinoids and TRAIL: Two cooperating Actors to Fight Against Cancer. Litwack G. Vitamins and Hormones. Vol. 67:2004;319-345 Academic, Elsevier
5. Laudet V., Gronemeyer H. The Nuclear Receptor Facts Book. 2001;Academic, London
6. De Urquiza A.M., Liu S., Sjoberg M., Zetterstrom R.H., Griffiths W., Sjovall J., Perlmann T. Science. 290:2000;2140-2144
7. Stehlin-Gaon C., Willmann D., Zeyer D., Sanglier S., Van Dorsselaer A., Renaud J.P., Moras D., Schule R. Nat. Struct. Biol. 10:2003;820-825
8. Shaw N., Elholm M., Noy N. J. Biol. Chem. 278:2003;41589-41592
9. Salomoni P., Pandolfi P.P. Cell. 108:2002;165-170
10. Piazza F., Gurrieri C., Pandolfi P.P. Oncogene. 20:2001;7216-7222
11. Lin R.J., Sternsdorf T., Tini M., Evans R.M. Oncogene. 20:2001;7204-7215
12. De The H., Chelbi-Alix M.K. Oncogene. 20:2001;7136-7139
13. Slack J.L.Ç., Gallagher R.E. Cancer Treat. Res. 99:1999;75-124
14. Minucci S., Cioce M., Maccarana M., Pelicci P.G. Haematologica. 84:1999;70-71
15. Bourguet W., Germain P., Gronemeyer H. Trends Pharmacol. Sci. 21:2000;381-388
16. Renaud J.P., Moras D. Cell. Mol. Life Sci. 57:2000;1748-1769
17. Boehm M.F., Zhang L., Badea B.-A., White S.K., Mais D.E., Berger E., Suto C.M., Goldman M.E., Heyman R.A. J. Med. Chem. 37:1994;2930-2941
18. Apisarnthanarax N., Talpur R., Duvic M. Am. J. Clin. Dermatol. 3:2002;193-215
19. Krathen R.A., Ward S., Duvic M. Dermatology. 206:2003;142-147
20. Khuri F.R., Rigas J.R., Figlin R.A., Gralla R.J., Shin D.M., Munden R., Fox N., Huyghe M.R., Kean Y., Reich S.D., Hong W.K. J. Clin. Oncol. 19:2001;2626-2637
21. Yu K.-L., Spinazze P., Ostrowski J., Currier S.J., Pack E.J., Hammer L., Roalsvig T., Honeyman J.A., Tortolani D.R., Reczek P.R., Mansuri M., Starrett J.E. Jr. J. Med. Chem. 39:1996;2411-2421
22. Shealy Y.F., Krauth Ch.A., Riordan J.M., Sani Br.P. J. Med. Chem. 31:1988;1124-1130
23. Compound 1-3: Valla A., Prat V., Laurent A., Andriamialisoa Z., Giraud M., Labia R., Potier P. Eur. J. Org. Chem. 2001;1731-1734
24. Compound 4: Valla A., Prat V., Laurent A., Andriamialisoa Z., Cartier D., Giraud M., Labia R., Potier P. Helv. Chim. Acta. 84:2001;3423-3427
25. 2: C 77.50, H 8.36, N 4.30; found: C 77.31, H 8.59, N 4.19
26. Compound 7: Valla A., Andriamialisoa Z., Giraud M., Prat V., Laurent A., Labia R., Potier P. Tetrahedron. 56:2000;7211-7215
27. Ivanova D., Gaudon C., Rossin A., Bourguet W., Gronemeyer H. Bioorg. Med. Chem. 10:2002;2099-2102